Healthcare Industry News: benign prostatic hyperplasia
News Release - November 20, 2007
Ranbaxy Launches Ran(R)-Tamsulosin Hydrochloride Capsules in CanadaTORONTO, Nov. 20 (Healthcare Sales & Marketing Network) -- Ranbaxy Pharmaceuticals Canada Inc. (RPCI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL had received approval in Canada to manufacture and market Tamsulosin Hydrochloride Capsules 0.4 mg from Health Canada, Therapeutic Products Directorate (TPD). This product has proven to be bio- equivalent to Flomax(R) Capsules which is indicated for the treatment of benign prostatic hyperplasia (BPH). The total market for both generic and brand Tamsulosin Hydrochloride Capsules in Canada is CAD $22 million (IMS-MAT: March 2007).
"We are pleased to receive this approval from TPD for Tamsulosin Hydrochloride Capsules that will expand Ranbaxy's expanding product portfolio of accessible and affordable generic product offerings. We are also quite proud of the fact that this formulation was fully developed within our parent company Ranbaxy Laboratories Limited, which further demonstrates the capabilities and competencies of the Ranbaxy organization. This is the fourth product to be added to our product portfolio through this pathway in 2007. RPCI's Sales Team will be offering Ran(R)-Tamsulosin immediately under the Ranbaxy label in all of the Canadian provinces that now provides another option to pharmacist for this molecule, that will be of benefit to both patients and the Canadian Health Care system," said Paul Drake, President, RPCI.
Ranbaxy Pharmaceuticals-Canada Inc. (RPCI) based in Mississauga, Ontario, Canada, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India's largest pharmaceutical company. RPCI is engaged in the sale and distribution of generic prescription products in the Canadian healthcare system.
Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.
Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies", resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 11 countries.
*Flomax(R) is a registered trademark of Boehringer Ingelheim, Canada
Source: Ranbaxy Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.